摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

14-methylpentadecanal | 62028-96-0

中文名称
——
中文别名
——
英文名称
14-methylpentadecanal
英文别名
isocetylaldehyde;Isohexadecanal
14-methylpentadecanal化学式
CAS
62028-96-0
化学式
C16H32O
mdl
——
分子量
240.429
InChiKey
IKBYSGSLCRPWRO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    36°C (estimate)
  • 沸点:
    313.15°C (estimate)
  • 密度:
    0.8264 (estimate)
  • LogP:
    6.871 (est)

计算性质

  • 辛醇/水分配系数(LogP):
    6.8
  • 重原子数:
    17
  • 可旋转键数:
    13
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.94
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    14-methylpentadecanal三乙胺双环己基(三氟甲烷磺酰氧基)硼烷 作用下, 以 正己烷二氯甲烷乙腈 为溶剂, 反应 7.83h, 生成
    参考文献:
    名称:
    结构分配,全合成和葡糖脂素A的磷酸酶调节活性的评估。
    摘要:
    glucolipsin A的先前未知的立体结构(1),复杂糖脂赋有葡糖激酶活化性能,被明确鉴定为(2 - [R,2' - [R,3小号,3'小号)由它的光谱的比较和分析数据与那些所有可能的C 2对称立体异构体。这套大分子二醇是通过以下步骤制备的:包括辅助引导的醛醇缩合反应,所得的β-羟基酸衍生物与三氯乙酰亚氨酸盐7的糖苷化反应,然后水解所用助剂。如此形成的羟基酸经过2-氯-1,3-二甲基咪唑啉鎓氯化物(22)作为活化剂介导的大二内酯化反应。仅在存在混合钾阳离子的情况下,这种转化才具有很高的生产力,钾离子有可能充当模板,以有利的头尾相接的方式预组织两个底物分子。对葡糖脂酶和类似物进行酶分析,结果表明该类型的糖缀合物可有效抑制具有IC 50的双重特异性磷酸酶Cdc25A的活性值在低微摩尔范围内,而在体外对酪氨酸磷酸酶PTP1B几乎没有活性。将该活性谱与先前在该实验室中制备的其他糖脂的活性谱进行了比较,包括环病毒素B
    DOI:
    10.1021/jo035079f
  • 作为产物:
    描述:
    14-methyl-1-pentadecanolpyridinium chlorochromate 作用下, 以 二氯甲烷 为溶剂, 反应 2.0h, 以86%的产率得到14-methylpentadecanal
    参考文献:
    名称:
    结构分配,全合成和葡糖脂素A的磷酸酶调节活性的评估。
    摘要:
    glucolipsin A的先前未知的立体结构(1),复杂糖脂赋有葡糖激酶活化性能,被明确鉴定为(2 - [R,2' - [R,3小号,3'小号)由它的光谱的比较和分析数据与那些所有可能的C 2对称立体异构体。这套大分子二醇是通过以下步骤制备的:包括辅助引导的醛醇缩合反应,所得的β-羟基酸衍生物与三氯乙酰亚氨酸盐7的糖苷化反应,然后水解所用助剂。如此形成的羟基酸经过2-氯-1,3-二甲基咪唑啉鎓氯化物(22)作为活化剂介导的大二内酯化反应。仅在存在混合钾阳离子的情况下,这种转化才具有很高的生产力,钾离子有可能充当模板,以有利的头尾相接的方式预组织两个底物分子。对葡糖脂酶和类似物进行酶分析,结果表明该类型的糖缀合物可有效抑制具有IC 50的双重特异性磷酸酶Cdc25A的活性值在低微摩尔范围内,而在体外对酪氨酸磷酸酶PTP1B几乎没有活性。将该活性谱与先前在该实验室中制备的其他糖脂的活性谱进行了比较,包括环病毒素B
    DOI:
    10.1021/jo035079f
点击查看最新优质反应信息

文献信息

  • [EN] FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF<br/>[FR] DERIVES DE LA PYRIMIDIN-4(3H)-ONE A CYCLES FUSIONNES, SPN PROCEDE DE PREPARATION ET SES UTILISATIONS
    申请人:SANKYO CO
    公开号:WO2003106435A1
    公开(公告)日:2003-12-24
    AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.
    新化合物具有以下式(I)的结构,其药学上可接受的盐和酯可以调节LXR功能,从而表现出优秀的抗动脉粥样硬化和抗炎活性:其中:A代表芳基或杂环芳基;R1、R2和R3相同或不同,每个代表氢、羟基、硝基、氰基、氨基、卤素、羧基、氨基甲酰基、巯基、烷基、卤代烷基、烷基羰氧基、烷氧基、烷硫基、烷磺基、烷基氨基、二烷基氨基、烷基羰基氨基、N-(烷基羰基)-N-(烷基)氨基、烷氧羰基氨基、N-(烷氧羰基)-N-(烷基)氨基、烷磺酰氨基、N-(烷磺酰基)-N-(烷基)氨基、卤代烷基磺酰氨基、N-(卤代烷基磺酰基)-N-(烷基)氨基、烷基羰基、烷氧羰基、烷基氨基羰基或二烷基氨基羰基,或R1和R2一起是亚烷二氧基;R4和R5相同或不同,每个代表氢、羟基、氨基、卤素、巯基、烷基、卤代烷基、烷氧基、烷氧羰基或烷硫基;X代表氢、羟基、卤素、烷氧基或卤代烷氧基;Y代表可选择取代的烷基、环烷基、杂环烷基、芳基、环烷基烷基、杂环烷基烷基或芳基烷基。
  • OXIME ETHER DERIVATIVE AND BACTERICIDE FOR AGRICULTURAL AND HORTICULTURAL USE
    申请人:Nippon Soda Co., Ltd.
    公开号:EP2314570A1
    公开(公告)日:2011-04-27
    Provided is a fungicide for agriculture and horticulture containing at least one of oxime ether derivative represented by Formula (I) or a salt thereof (wherein X represents a halogen atom, a C1-C20 alkyl group or the like, R1 and R2 each independently represent a hydrogen atom, a C1-C20 alkyl group, or the like, R3 represents a hydrogen atom, a C1-C20 alkyl group, or the like, R4 represents a hydrogen atom, a C1-C20 alkyl group, or the like, R5 represents a hydrogen atom or the like, Y represents an oxygen atom or the like, Z represents an oxygen atom or the like, Q represents an aryl group or the like, m represents an integer of 0 to 8, and n represents an integer of 0 to 4).
    提供一种用于农业和园艺的杀菌剂,含有由式(I)表示的至少一种肟醚衍生物或其盐(其中X代表卤素原子、C1-C20烷基或类似物,R1和R2分别独立地代表氢原子、C1-C20烷基或类似物,R3代表氢原子、C1-C20烷基或类似物,R4代表氢原子、C1-C20烷基或类似物,R5代表氢原子或类似物,Y代表氧原子或类似物,Z代表氧原子或类似物,Q代表芳基或类似物,m代表0到8的整数,n代表0到4的整数)。
  • CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA
    申请人:MITSUBISHI TANABE PHARMA CORPORATION
    公开号:US20220002336A1
    公开(公告)日:2022-01-06
    The present invention provides a novel bridged artificial nucleic acid and an oligomer containing the same as a monomer. The present invention provides specifically a compound represented by general formula (I) (wherein each symbol is the same as defined in the specification) or salts thereof; as well as an oligonucleotide compound represented by general formula (I′) (wherein each symbol is the same as defined in the specification) or salts thereof.
    本发明提供了一种新型的桥接人工核酸和含有该人工核酸作为单体的寡聚物。本发明具体提供了一种由通式(I)表示的化合物(其中每个符号与规范中定义的相同)或其盐;以及由通式(I')表示的寡核苷酸化合物(其中每个符号与规范中定义的相同)或其盐。
  • [EN] FUSED LACTAM COMPOUNDS<br/>[FR] COMPOSES DE LACTAME CONDENSE
    申请人:PFIZER JAPAN INC
    公开号:WO2005035523A1
    公开(公告)日:2005-04-21
    This invention provides a compound the formula (I), wherein R1 represents an aryl group having from 6 to 10 ring carbon atoms etc.; R2 represents a hydrogen atom etc., n epresents 0, 1 or 2; said heteroaryl group is unsubstituted or substituted and said ary is substituted by at least one substituer,t selected from the group consisting of substituents a; said substituents a are selected from the group 10 consisting of halogen ate ms, alkyl groups having from 1 to 6 carbon atoms etc.; or a pharmaceutically ac eptable ester of such compound, or a pharmaceutically ac eptable salt thereof. These compou ds are useful for the treatment of disease conditions caused 15 by overactivation of N DA NR2B receptor such of pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety, migraine, or the like in mammalian, especially humans. This invention also provides a pharmaceutical composi ion comprising the above compound.
    本发明提供了一种具有公式(I)的化合物,其中R1代表一个具有6到10个环碳原子的芳基团等;R2代表一个氢原子等,n代表0、1或2;所说的杂芳基团未取代或取代,所说的芳基至少被一个从由取代基a组成的组中选择的取代基t所取代;所说的取代基a是从由卤素原子、具有1到6个碳原子的烷基团等组成的组中选择的;或者该化合物的药物可接受的酯,或者其药物可接受的盐。这些化合物用于治疗由NDA NR2B受体过度激活引起的疾病状况,如疼痛、中风、创伤性脑损伤、帕金森病、阿尔茨海默病、抑郁症、焦虑症、偏头痛或类似疾病,特别是在哺乳动物中,特别是人类。本发明还提供了一种包含上述化合物的药物组合物。
  • Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
    申请人:SANKYO COMPANY, LIMITED
    公开号:US20040054173A1
    公开(公告)日:2004-03-18
    Compounds having activity against production of an inflammatory cytokine of formula (I)′: 1 A′ is pyrrole; R 1′ is phenyl or naphthyl; R 2′ is pyridyl or pyrimidinyl; R 3′ is (IIa)′, (IIb)′ or (IIc)′: 2 m′ is 1; E′ is nitrogen; D′ is >C(R 5′ )—, R 5′ is hydrogen, Substituent &agr;′ or Substituent &bgr;′; B′ is nitrogen-containing 5-membered heterocyclic; R 4′ is 1 to 3 substituents from Substituent &agr;′, Substituent &bgr;′ and Substituent &ggr;′; R 1′ and R 3′ are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R 2′ ; Substituent &agr;′ is hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NR a′ R b′ ; R a′ and R b′ are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or R a′ and R b′ with the nitrogen atom form a heterocyclyl; Substituent &bgr;′ is alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent &ggr;′ is oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.
    具有对抗公式(I)′炎症细胞因子生成活性的化合物: 1 A′是吡咯;R 1′ 是苯基或萘基;R 2′ 是吡啶基或嘧啶基;R 3′ 是(IIa)′,(IIb)′或(IIc)′: 2 m′是1;E′是氮;D′是>C(R 5′ )—, R 5′ 是氢,取代基α′或取代基β′;B′是含氮的5-成员杂环;R 4′ 是来自取代基α′,取代基β′和取代基γ′的1至3个取代基;R 1′ 和R 3′ 分别与吡咯环上与R 2′ 相连的吡咯原子的两个相邻原子成键;取代基α′是羟基,硝基,氰基,卤素,烷氧基,卤代烷氧基,烷基亚砜,卤代烷基亚砜或—NR a′ R b′ ;R a′ 和R b′ 是氢,烷基,烯基,炔基,芳烷基或烷基亚磺酰基,或者R a′ 和R b′ 与氮原子形成杂环;取代基β′是烷基,烯基,炔基,芳烷基或环烷基;取代基γ′是氧代,羟基亚胺,烷氧基亚胺,亚烷基,亚烷基二氧,烷基亚磺酰基,烷基亚磺酰基,芳基,芳氧基,亚烷基或芳亚烷基。
查看更多